From a pediatric alopecia areata approval to head-to-head TYK2 data at EADV, here are 7 dermatology stories from September 2026.
Commentary|Videos|July 11, 2025
Advocating for Patients With Psoriasis: Securing Access to Nonsteroidal Topicals Like Roflumilast
Author(s)Mona Shahriari, MD, FAAD, David Hartigan
Fact checked by: Victoria Johnson
In this video, the last in a 6-part series, panelists discuss recent advancements in PsO management.
Advertisement
Advertisement
In this HCPLive RX Review Special Report, Mona Shahriari, MD, Associate Clinical Professor of Dermatology at Yale University, sits down with David Hartigan, a biologic coordinator with Biologic Coordinators of Dermatology, to discuss strategies for overcoming access challenges to non-steroidal topicals like roflumilast foam for people with plaque psoriasis (PsO) on the scalp.
Related to this article
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.
Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
Advertisement
Advertisement